NCT03033524View on ClinicalTrials.gov

Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 4, 2016

Primary Completion Date

June 2, 2017

Study Completion Date

June 2, 2017

Conditions
Recurrent Glioblastoma
Interventions
DRUG

TTAC-0001

Calculated amount of drug will be diluted with normal saline and administered intravenously.

Sponsors

Lead Sponsor

PharmAbcine
All Listed Sponsors
lead

PharmAbcine

INDUSTRY